

# **Myelodysplastic Syndrome Market Research Report by Route of Administration (Oral and Parenteral), by Drug Class (Alkylating Agents, Cytotoxic Antibiotics, and Topoisomerase Inhibitors) - Global Forecast to 2025 - Cumulative Impact of COVID-19**

<https://marketpublishers.com/r/M0D465E7E06DEN.html>

Date: February 2021

Pages: 187

Price: US\$ 3,949.00 (Single User License)

ID: M0D465E7E06DEN

## **Abstracts**

### Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR, GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Myelodysplastic Syndrome Market is expected to grow from USD 1,959.67 Million in 2020 to USD 3,020.95 Million by the end of 2025.
2. The Global Myelodysplastic Syndrome Market is expected to grow from EUR 1,718.28 Million in 2020 to EUR 2,648.83 Million by the end of 2025.
3. The Global Myelodysplastic Syndrome Market is expected to grow from GBP 1,527.55 Million in 2020 to GBP 2,354.81 Million by the end of 2025.
4. The Global Myelodysplastic Syndrome Market is expected to grow from JPY 209,147.32 Million in 2020 to JPY 322,412.64 Million by the end of 2025.
5. The Global Myelodysplastic Syndrome Market is expected to grow from AUD 2,845.71 Million in 2020 to AUD 4,386.83 Million by the end of 2025.

### Market Segmentation & Coverage:

This research report categorizes the Myelodysplastic Syndrome to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Route of Administration, the Myelodysplastic Syndrome Market studied across Oral and Parenteral.

Based on Drug Class, the Myelodysplastic Syndrome Market studied across Alkylating Agents, Cytotoxic Antibiotics, and Topoisomerase Inhibitors.

Based on Geography, the Myelodysplastic Syndrome Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

#### Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Myelodysplastic Syndrome Market including Acceleron Pharma, Amgen, Bellicum Pharmaceuticals, BioLineRx, Celator Pharmaceuticals, Celgene, Cornerstone Pharmaceuticals, Eli-Lilly, GlaxoSmithKline, and Novartis.

#### Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so far and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

#### 360iResearch FPNV Positioning Matrix:

The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Myelodysplastic Syndrome Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

#### 360iResearch Competitive Strategic Window:

The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

1. **Market Penetration:** Provides comprehensive information on the market offered by the key players
2. **Market Development:** Provides in-depth information about lucrative emerging markets and analyzes the markets
3. **Market Diversification:** Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. **Competitive Assessment & Intelligence:** Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. **Product Development & Innovation:** Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Myelodysplastic Syndrome Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Myelodysplastic Syndrome Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Myelodysplastic Syndrome Market?
4. What is the competitive strategic window for opportunities in the Global Myelodysplastic Syndrome Market?
5. What are the technology trends and regulatory frameworks in the Global Myelodysplastic Syndrome Market?
6. What are the modes and strategic moves considered suitable for entering the Global Myelodysplastic Syndrome Market?

## Contents

### 1. PREFACE

- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Stakeholders

### 2. RESEARCH METHODOLOGY

- 2.1. Research Process
  - 2.1.1. Define: Research Objective
  - 2.1.2. Determine: Research Design
  - 2.1.3. Prepare: Research Instrument
  - 2.1.4. Collect: Data Source
  - 2.1.5. Analyze: Data Interpretation
  - 2.1.6. Formulate: Data Verification
  - 2.1.7. Publish: Research Report
  - 2.1.8. Repeat: Report Update
- 2.2. Research Execution
  - 2.2.1. Initiation: Research Process
  - 2.2.2. Planning: Develop Research Plan
  - 2.2.3. Execution: Conduct Research
  - 2.2.4. Verification: Finding & Analysis
  - 2.2.5. Publication: Research Report
- 2.3. Research Outcome

### 3. EXECUTIVE SUMMARY

- 3.1. Introduction
- 3.2. Market Outlook
- 3.3. Drug Class Outlook
- 3.4. Route of Administration Outlook
- 3.5. Geography Outlook
- 3.6. Competitor Outlook

## **4. MARKET OVERVIEW**

- 4.1. Introduction
- 4.2. Cumulative Impact of COVID-19

## **5. MARKET INSIGHTS**

- 5.1. Market Dynamics
  - 5.1.1. Drivers
  - 5.1.2. Restraints
  - 5.1.3. Opportunities
  - 5.1.4. Challenges
- 5.2. Porters Five Forces Analysis
  - 5.2.1. Threat of New Entrants
  - 5.2.2. Threat of Substitutes
  - 5.2.3. Bargaining Power of Customers
  - 5.2.4. Bargaining Power of Suppliers
  - 5.2.5. Industry Rivalry

## **6. GLOBAL MYELODYSPLASTIC SYNDROME MARKET, BY ROUTE OF ADMINISTRATION**

- 6.1. Introduction
- 6.2. Oral
- 6.3. Parenteral

## **7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET, BY DRUG CLASS**

- 7.1. Introduction
- 7.2. Alkylating Agents
- 7.3. Cytotoxic Antibiotics
- 7.4. Topoisomerase Inhibitors

## **8. AMERICAS MYELODYSPLASTIC SYNDROME MARKET**

- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil

- 8.4. Canada
- 8.5. Mexico
- 8.6. United States

## **9. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET**

- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. South Korea
- 9.10. Thailand

## **10. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET**

- 10.1. Introduction
- 10.2. France
- 10.3. Germany
- 10.4. Italy
- 10.5. Netherlands
- 10.6. Qatar
- 10.7. Russia
- 10.8. Saudi Arabia
- 10.9. South Africa
- 10.10. Spain
- 10.11. United Arab Emirates
- 10.12. United Kingdom

## **11. COMPETITIVE LANDSCAPE**

- 11.1. FPNV Positioning Matrix
  - 11.1.1. Quadrants
  - 11.1.2. Business Strategy
  - 11.1.3. Product Satisfaction

- 11.2. Market Ranking Analysis
- 11.3. Market Share Analysis
- 11.4. Competitor SWOT Analysis
- 11.5. Competitive Scenario
  - 11.5.1. Merger & Acquisition
  - 11.5.2. Agreement, Collaboration, & Partnership
  - 11.5.3. New Product Launch & Enhancement
  - 11.5.4. Investment & Funding
  - 11.5.5. Award, Recognition, & Expansion

## **12. COMPANY USABILITY PROFILES**

- 12.1. Acceleron Pharma
- 12.2. Amgen
- 12.3. Bellicum Pharmaceuticals
- 12.4. BioLineRx
- 12.5. Celator Pharmaceuticals
- 12.6. Celgene
- 12.7. Cornerstone Pharmaceuticals
- 12.8. Eli-Lilly
- 12.9. GlaxoSmithKline
- 12.10. Novartis

## **13. APPENDIX**

- 13.1. Discussion Guide
- 13.2. License & Pricing

## List Of Tables

### LIST OF TABLES

TABLE 1. CURRENCY CONVERSION RATES

TABLE 2. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 3. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 4. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 5. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 6. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY PARENTERAL, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 7. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 8. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ALKYLATING AGENTS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 9. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY CYTOTOXIC ANTIBIOTICS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 10. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 11. AMERICAS MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 12. AMERICAS MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 13. AMERICAS MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 14. ARGENTINA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 15. ARGENTINA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 16. BRAZIL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 17. BRAZIL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF



ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 18. CANADA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 19. CANADA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 20. MEXICO MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 21. MEXICO MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 22. UNITED STATES MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 23. UNITED STATES MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 24. ASIA-PACIFIC MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 25. ASIA-PACIFIC MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 26. ASIA-PACIFIC MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 27. AUSTRALIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 28. AUSTRALIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 29. CHINA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 30. CHINA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 31. INDIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 32. INDIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 33. INDONESIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 34. INDONESIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 35. JAPAN MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 36. JAPAN MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 37. MALAYSIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 38. MALAYSIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 39. PHILIPPINES MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 40. PHILIPPINES MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 41. SOUTH KOREA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 42. SOUTH KOREA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 43. THAILAND MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 44. THAILAND MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 45. EUROPE, MIDDLE EAST & AFRICA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 46. EUROPE, MIDDLE EAST & AFRICA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 47. EUROPE, MIDDLE EAST & AFRICA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 48. FRANCE MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 49. FRANCE MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 50. GERMANY MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 51. GERMANY MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 52. ITALY MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 53. ITALY MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 54. NETHERLANDS MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 55. NETHERLANDS MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 56. QATAR MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 57. QATAR MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 58. RUSSIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 59. RUSSIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 60. SAUDI ARABIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 61. SAUDI ARABIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 62. SOUTH AFRICA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 63. SOUTH AFRICA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 64. SPAIN MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 65. SPAIN MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 66. UNITED ARAB EMIRATES MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 67. UNITED ARAB EMIRATES MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 68. UNITED KINGDOM MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 69. UNITED KINGDOM MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 70. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: SCORES

TABLE 71. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: BUSINESS STRATEGY

TABLE 72. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: PRODUCT SATISFACTION

TABLE 73. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: RANKING

TABLE 74. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: MERGER & ACQUISITION

TABLE 75. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP

TABLE 76. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT

TABLE 77. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: INVESTMENT & FUNDING

TABLE 78. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: AWARD, RECOGNITION, & EXPANSION

TABLE 79. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: LICENSE & PRICING

## List Of Figures

### LIST OF FIGURES

FIGURE 1. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: RESEARCH PROCESS

FIGURE 2. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: RESEARCH EXECUTION

FIGURE 3. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, 2020 VS 2025 (USD MILLION)

FIGURE 4. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)

FIGURE 5. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 (USD MILLION)

FIGURE 6. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)

FIGURE 7. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, 2018-2025 (USD MILLION)

FIGURE 8. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 9. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 11. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: MARKET DYNAMICS

FIGURE 12. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: PORTERS FIVE FORCES ANALYSIS

FIGURE 13. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2025 (%)

FIGURE 14. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2025 (USD MILLION)

FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025

FIGURE 16. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ORAL, 2020 VS 2025 (USD MILLION)

FIGURE 17. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY PARENTERAL, 2020 VS 2025 (USD MILLION)

FIGURE 18. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (%)

FIGURE 19. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (USD MILLION)

FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2025

FIGURE 21. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY ALKYLATING AGENTS, 2020 VS 2025 (USD MILLION)

FIGURE 22. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY CYTOTOXIC ANTIBIOTICS, 2020 VS 2025 (USD MILLION)

FIGURE 23. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2020 VS 2025 (USD MILLION)

FIGURE 24. AMERICAS MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 25. AMERICAS MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 26. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 27. ARGENTINA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 28. BRAZIL MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 29. CANADA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 30. MEXICO MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 31. UNITED STATES MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 32. ASIA-PACIFIC MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 33. ASIA-PACIFIC MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 34. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 35. AUSTRALIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 36. CHINA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 37. INDIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY



GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 38. INDONESIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 39. JAPAN MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 40. MALAYSIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 41. PHILIPPINES MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 42. SOUTH KOREA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 43. THAILAND MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 44. EUROPE, MIDDLE EAST & AFRICA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 45. EUROPE, MIDDLE EAST & AFRICA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 46. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 47. FRANCE MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 48. GERMANY MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 49. ITALY MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 50. NETHERLANDS MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 51. QATAR MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 52. RUSSIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 53. SAUDI ARABIA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 54. SOUTH AFRICA MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 55. SPAIN MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 56. UNITED ARAB EMIRATES MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 57. UNITED KINGDOM MYELOYDYSPLASTIC SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 58. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: 360IRESEARCH FPNV POSITIONING MATRIX

FIGURE 59. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: 360IRESEARCH MARKET SHARE ANALYSIS

FIGURE 60. GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET: COMPETITOR SWOT ANALYSIS

FIGURE 61. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL MYELOYDYSPLASTIC SYNDROME MARKET, BY TYPE



## I would like to order

Product name: Myelodysplastic Syndrome Market Research Report by Route of Administration (Oral and Parenteral), by Drug Class (Alkylating Agents, Cytotoxic Antibiotics, and Topoisomerase Inhibitors) - Global Forecast to 2025 - Cumulative Impact of COVID-19

Product link: <https://marketpublishers.com/r/M0D465E7E06DEN.html>

Price: US\$ 3,949.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M0D465E7E06DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970